z-logo
open-access-imgOpen Access
Peritoneal absorption of moxalactam
Author(s) -
Nancy M. Stephens,
Nouhad O. Kronfol,
Berry J. Kline,
Ron E. Polk
Publication year - 1983
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.24.1.39
Subject(s) - moxalactam , liter , peritoneal dialysis , peritonitis , medicine , continuous ambulatory peritoneal dialysis , latamoxef , pharmacokinetics , absorption (acoustics) , chemistry , pharmacology , antibiotics , cephalosporin , biochemistry , physics , acoustics
We evaluated the rate and extent of the systemic absorption of moxalactam given intraperitoneally to patients with peritonitis and end-stage renal disease who were being maintained on continuous ambulatory peritoneal dialysis. Moxalactam was administered at a concentration of 200 mg per 2-liter dialysate for the first dose, followed by 60 mg per 2-liter exchange for 23 1-h exchanges. Moxalactam concentrations in serum (mean +/- standard deviation) were 2.5 +/- 0.9 mg/liter after the first hourly dialysis, increasing to 10.3 +/- 4.8 mg/liter after 24 h of drug administration. Moxalactam levels in serum at 1 h were above the minimal inhibitory concentrations for most gram-negative organisms except Pseudomonas aeruginosa. No adverse effects of the drug were observed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here